Clinical trial
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy…
NCT00356681 · Amgen, Industry · Terminated
Key facts
| NCT number | NCT00356681 |
|---|---|
| Title | A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer |
| Official title | A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Tumors, Breast Cancer, Locally Recurrent and Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | AMG 706 placebo, Bevacizumab, AMG 706, Paclitaxel |
| Enrollment | 282 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Aug 1, 2012 |
| First posted | Jul 26, 2006 |
| Last update posted | Oct 15, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: